Pfizer And J&J Settle Remicade Antitrust Litigation

Long-Running Case Over Infliximab Biosimilars Resolved On Confidential Terms

Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.

Settlement Law Legal Gavel
Pfizer and J&J have settled the Remicade antitrust lawsuit • Source: Alamy

Antitrust litigation between Pfizer and Johnson & Johnson over US contracts and deals for the Remicade (infliximab) brand that were alleged to have been set up so as to dampen biosimilar competition has been dismissed after the companies settled on confidential terms.

[Sidebar#GB139914]

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business